Amylyx Pharmaceuticals AMLX
NASDAQ AMLX
$29.09 -0.19 (-0.65%)
As of: Sep 30, 2026 · 10:22 AM EDT

Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024)

Updated

Amylyx Pharmaceuticals' EBT Margin came in at -345.69% for FY2024, down 359.95 percentage points from 14.26% in FY2023.

Analysis

Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024) Analysis & Trends

Going back to FY2021, Amylyx Pharmaceuticals' EBT Margin data covers 4 years.

  • EBT Margin carries a three-year change of +30507.29 percentage points (FY2021 to FY2024).
  • The five-year range for annual EBT Margin is -30852.98% (FY2021) to 14.26% (FY2023).
  • Per Business Quant, earlier years put EBT Margin at 14.26% in FY2023 (+903.15 pp), -888.89% in FY2022 (+29964.09 pp) and -30852.98% in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 26.66%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 25.18%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -4.11%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 29.63%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 18.19%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 27.53%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -131.41%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -4.34%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 41.75%
10 Amylyx Pharmaceuticals 3.32 Bn 3.32 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 -17,476.92%
Jun 30, 2024 -7,106.55%
Mar 31, 2024 -133.74%
Dec 31, 2023 5.97%
Sep 30, 2023 21.82%
Jun 30, 2023 24.44%
Mar 31, 2023 1.96%
Dec 31, 2022 -192.48%
Sep 30, 2022 -15,617.68%
Sep 30, 2021 -8,120.00%
API Access

Amylyx Pharmaceuticals EBT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt-margin&ticker=AMLX&period=max&api_key=YOUR_API_KEY